Effects of clomiphene and tamoxifen on pregnancy rate in infertile women

INTERVENTION: Intervention 1: Prescription of 2tablet ( 40mg) tamoxifenfir 5 days from day 3‐7 of menstrual cycle, serial sonography in day 12‐16 was done for evaluation of endometrial thickness and pattern and number of mature follicles. And after reaching at least are follicle to =18mm, injection of 5000Iu HCG was done and ultimately control the incidence of pregnancy in women. Intervention 2: Prescription of 150mg clomiphen citrate for 5 days from day 3‐7 of menstrual cycle, serial sonography in day 12‐16 was done for evaluation endometrial thickness and pattern and number of mature follicles, and after reaching at least one follicle to =18mm,5000Iu HCG was injected and ultimately control the incidence of pregnancy in women. Prescription of 150mg clomiphen citrate for 5 days from day 3‐7 of menstrual cycle, serial sonography in day 12‐16 was done for evaluation endometrial thickness and pattern and number of mature follicles, and after reaching at least one follicle to =18mm,5000Iu HCG was injected and ultimately control the incidence of pregnancy in women Prescription of 2tablet ( 40mg) tamoxifenfir 5 days from day 3‐7 of menstrual cycle, serial sonography in day 12‐16 was done for evaluation of endometrial thickness and pattern and number of mature follicles. And after reaching at least are follicle to =18mm, injection of 5000Iu HCG was done and ultimately control the incidence of pregnancy in women Treatment ‐ Drugs CONDITION: Ovarian dysfunction, unspecified Ovarian dysfunction, unspecified. ; Ovarian dysfunction, unspecified PRIMARY OUTCOME: Pregnancy rate. Timepoint: End of menstural cycle. Method of measurement: Serum BhCG. SECONDARY OUTCOME: Abortion rate. Timepoint: End of menstrual cycle. Method of measurement: The incidence of menstrual bleeding and new. Multigestation rate. Timepoint: End of menstrual cycle. Method of measurement: Sonography. Ovarian hyperstimulation syndrome. Timepoint: End of menstrual cycle. Method of measurement: Clinical and ultrasound. Side effects such as headaches, dizziness, blurred vision, nausea and vomiting. Timepoint: During the treatment cycle. Method of measurement: Ask the patient. INCLUSION CRITERIA: Inclusion criterion: infertile women with ovulation disorders without other cause of infertility. Exclusion criteria: abnormal semen analysis and HSG or laparoscopy; age over 40; myoma; hyperprolactinema; FSH over12; hypothyroidism; hyperthyroidism; previous history of induction of ovulation; renal & liver disease and contraindication of clomiphen citrate and tamoxifen.